Propanc Biopharma (NASDAQ:PPCB – Get Free Report) announced that its Board of Directors has approved a stock buyback program on Thursday, June 11th, RTT News reports. The company plans to repurchase $5.00 million in shares. This repurchase authorization allows the company to buy up to 162.3% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.
Propanc Biopharma Trading Up 80.0%
NASDAQ PPCB traded up $1.08 during trading on Thursday, hitting $2.43. 174,239,764 shares of the company traded hands, compared to its average volume of 65,234. Propanc Biopharma has a 12 month low of $1.30 and a 12 month high of $270.25. The business has a fifty day simple moving average of $2.27 and a 200 day simple moving average of $7.23. The company has a market capitalization of $5.54 million, a P/E ratio of -0.10 and a beta of 3.48.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Propanc Biopharma presently has a consensus rating of “Sell”.
About Propanc Biopharma
Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.
The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.
Read More
- Five stocks we like better than Propanc Biopharma
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
